About Predictive Oncology (NASDAQ: POAI)
The leading edge of a new frontier in drug discovery
As a science-driven company on the leading edge of oncology drug discovery, Predictive Oncology offers an unrivaled suite of solutions for the biopharma industry. Through the integration of scientific rigor and machine learning, the company has developed the ability to advance molecules into medicine more confidently by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the world’s largest privately held biobank of over 150K tumor samples. Predictive Oncology’s solutions additionally include tumor models, biologics development, formulation design, a GMP facility, a CLIA laboratory and substantial scientific domain expertise.
Our vision
We bring hope to cancer patients.
Our mission
Our mission at Predictive Oncology is to change the landscape of oncology drug discovery and enable the development of more effective therapies for the treatment of cancer. By harnessing the power of machine learning, scientific rigor and biologics, we can improve the probability of success and advance drug compounds with a higher degree of confidence.
Our why
At the end of the day, we know there is a cancer patient waiting for therapies to be developed, hoping for a new and effective treatment to get into the hands of the clinician that can help improve their quality of life, extend their life or even cure their cancer—we are that hope.
Meet our team
Get to know our Leadership Team and Board of Directors.
Let’s discover and develop together.
We want to hear about your process challenges—and identify ways to solve them together. Complete the form to get in touch with our team of experts.
News & resources
Dominic Pollard of Cancer Research Horizons and Dr. Pamela Bush of Predictive Oncology discuss the potential impact of their collaboration and how it can advance...
Cancer Research Horizons to incorporate PEDAL into future drug discovery processes to enable drug development on a global scale 11 marketed drugs 2nd largest oncology...
Proactive Investor’s Natalie Stoberman met with Raymond F. Vennare, CEO of Predictive Oncology, and Javier Torres-Roca, MD, Co-Founder and CEO of Cvergenx, Inc., to discuss...